• Our Company
  • About Us
  • About Xanamem^®
  • Our Team
  • Recent Annual Reports
  • Our Strategic Priorities
  • Corporate Governance
• Xanamem^®
  • The Cortisol Hypothesis
  • Mechanism of Action
  • Publications
• Clinical Trials
  • Clinical Development Pipeline
    • Cognitive Impairment in early Alzheimer’s Disease
    • Cognitive Impairment in MDD
    • Anxiety, sleep & behavioral problems in Fragile X Syndrome
  • Patient Portal
  • Participate in clinical trials
    • The XanaCIDD Depression Clinical Trial
    • The XanaMIA Phase 2b Alzheimer’s Trial
  • Publications
• Investor Centre
  • Share Price
  • ASX Announcements
  • Corporate Presentations
  • Analyst Reports
  • Financial Results Centre
  • Annual General Meeting
  • General Meeting
  • Financial Calendar
  • Right to Receive Documents
  • Frequently Asked Questions
  • Investor Contacts
• News
• Contact Us